Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Neil Osterweil

    News

    Sex differences in COPD slow to be recognized, treated

    Author:
    Neil Osterweil
    Publish date: April 12, 2022

    Science and society have been slow to catch on to sex-based differences in clinical presentation and response to...

    • Read More

    News

    Global melanoma incidence high and on the rise

    Author:
    Neil Osterweil
    Publish date: April 5, 2022

    The highest incidence and mortality rates of cutaneous melanoma are in wealthy nations, a new study shows.

    • Read More

    News

    Adverse skin effects of cancer immunotherapy reviewed

    Author:
    Neil Osterweil
    Publish date: March 21, 2022

    “The desirable, immune-mediated oncologic response is often achieved at the cost of immune-related adverse events (irAEs) that may potentially...

    • Read More

    News

    Gene therapy for hemophilia A: `Truly transformative and liberating’

    Author:
    Neil Osterweil
    Publish date: March 17, 2022

    This first-generation gene therapy offers a new choice for care that could be 'truly transformative and liberating' for eligible men with...

    • Read More

    News

    CPAP has only small effect on metabolic syndrome

    Author:
    Neil Osterweil
    Publish date: March 15, 2022

    Although the benefit was small, CPAP was more effective than nasal strips at reversing the metabolic syndrome in...

    • Read More

    News

    Rare pediatric cancers persist 63 years after nuclear accident

    Author:
    Neil Osterweil
    Publish date: March 15, 2022

    Near Los Angeles, the parents of kids whose cluster of rare leukemias and other cancers may be linked to a 1959 partial meltdown at Santa Susana...

    • Read More

    News

    New gene signals for asthma-COPD overlap identified

    Author:
    Neil Osterweil
    Publish date: March 4, 2022

    A genome-wide association study of individuals with asthma-COPD overlap identified genetic variants that could...

    • Read More

    News

    High early recurrence rates with Merkel cell carcinoma

    Author:
    Neil Osterweil
    Publish date: March 3, 2022

    Approximately 95% of all recurrences happened within 3 years of the initial diagnosis in the prospective cohort study.

    • Read More

    News

    New hemophilia treatments: ‘Our cup runneth over’

    Author:
    Neil Osterweil
    Publish date: February 15, 2022

    A range of new options is emerging to treat hemophilia patients.

    • Read More

    News

    Handle with care: Managing IBD in older patients

    Author:
    Neil Osterweil
    Publish date: February 15, 2022

    Patients 60 and older with chronic or newly diagnosed IBD may have comorbidities or use medications that can interfere with IBD therapies.

    • Read More

    News

    Malnutrition common in patients with IBD

    Author:
    Neil Osterweil
    Publish date: February 14, 2022

    As many as 85% of patients hospitalized with IBD may be malnourished, dietary experts cautioned.

    • Read More

    News

    Breakthrough COVID-19 milder in vaccinated patients with IBD

    Author:
    Neil Osterweil
    Publish date: February 14, 2022

    Patients with inflammatory bowel disease who are vaccinated but still develop COVID experience milder disease than those who are unvaccinated.

    • Read More

    News

    Cystic fibrosis in retreat, but still unbeaten

    Author:
    Neil Osterweil
    Publish date: February 9, 2022

    Improvements in care and novel therapies have dramatically increased life expectancy and improved quality of...

    • Read More

    News

    ARFID or reasonable food restriction? The jury is out

    Author:
    Neil Osterweil
    Publish date: February 3, 2022

    Don’t jump to conclusions about avoidant restrictive food intake disorder in patients with gastrointestinal diseases, psychologists advise.

    • Read More

    News

    Monotherapy or one-two punch against EGFR-mutant NSCLC?

    Author:
    Neil Osterweil
    Publish date: January 27, 2022

    Clinicians debate whether combining other drugs with osimertinib adds anything but toxicity to the care of patients with EGFR-mutated NSCLC.

    • Read More

    Pages

    • « first
    • …
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery